Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment

Rheumatology (United Kingdom)

Volumn 52, Issue 9, 2013, Pages 1572-1582

  Collins, Emily S ^a,b   Galligan, Marie C ^b,c   Saldova, Radka ^c   Adamczyk, Barbara ^c   Abrahams, Jodie L ^c   Campbell, Matthew P ^c   Ng, Chin Teck ^a,d   Veale, Douglas J ^a   Murphy, Thomas B ^b   Rudd, Pauline M ^c   FitzGerald, Oliver ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING   (Ireland)

^d Faculty of Medicine   (Malaysia)

Author keywords

Anti TNF therapy; CRP; Galactosylation; IgG GO; Inflammation; Inflammatory arthritis; N glycosylation; Psoriatic arthritis; Rheumatoid arthritis; Sialylation

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLYCAN DERIVATIVE; IMMUNOGLOBULIN G; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-TNF THERAPY; CRP; GALACTOSYLATION; IGG-GO; INFLAMMATION; INFLAMMATORY ARTHRITIS; N-GLYCOSYLATION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIALYLATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD PROTEINS; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883029177     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket189     Document Type: Article

References (45)

1. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 19991473: 4-8.
2. Dwek RA, Butters TD, Platt FM et al. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 20021:65-75.
3. Grigorian A, Lee SU, Tian W et al. Control of T cellmediated autoimmunity by metabolite flux to N-glycan biosynthesis. J Biol Chem 2007282:20027-35.
4. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science 2001291:2364-9.
5. Morgan R, Gao G, Pawling J et al. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol 2004173:7200-8.
6. Grigorian A, Mkhikian H, Demetriou M. Interleukin-2, interleukin-7, T cell-mediated autoimmunity, and N-glycosylation. Ann N Y Acad Sci 20121253:49-57.
7. Alavi A, Axford JS. Sweet and sour: the impact of sugars on disease. Rheumatology 200847:760-70.
8. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers 200825:267-78.
9. Alavi A, Axford JS. Glyco-biomarkers: potential determinants of cellular physiology and pathology. Dis Markers 200825:193-205.
10. Parekh RB, Dwek RA, Sutton BJ et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985316:452-7.
11. Knezevic A, Polasek O, Gornik O et al. Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res 20098:694-701.
12. Yamada E, Tsukamoto Y, Sasaki R et al. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 199714:401-5.
13. Pucic M, Knezevic A, Vidic J et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 201110:M111.010090.
14. Parekh R, Roitt I, Isenberg D et al. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 1988167:1731-6.
15. Rook GAW, Steele J, Brealey R et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 1991;4:779-94.
16. Watson M, Rudd PM, Bland M et al. Sugar printing rheumatic diseases-a potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis Rheum 199942:1682-90.
17. Parekh RB, Roitt IM, Isenberg DA et al. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 19881:966-9.
18. Troelsen LN, Jacobsen S, Abrahams JL et al. IgG glycosylation changes and MBL2 polymorphisms: associations with markers of systemic inflammation and joint destruction in rheumatoid arthritis. J Rheumatol 201239:463-9.
19. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 20084:300-9.
20. Horiuchi T, Mitoma H, Harashima SI et al. Transmembrane TNF-alpha: structure, function and interaction with anti- TNF agents. Rheumatology 201049:1215-28.
21. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002301:418-26.
22. Van Beneden K, Coppieters K, Laroy W et al. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 200968:1360-5.
23. Croce A, Firuzi O, Altieri F et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 200721:303-14.
24. Pasek M, Duk M, Podbielska M et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients-changes during therapy. Glycoconj J 200623:463-71.
25. Ercan A, Cui J, Hazen MM et al. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther 201214:R43.
26. Royle L, Campbell MP, Radcliffe CM et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 2008376: 1-12.
27. R-Development-Core-Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
28. Pinheiro J, Bates D, DebRoy S et al. the R Core team. Nlme: linear and nonlinear mixed effects models. R package version 3.1-102, 2011.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 199557:289-300.
30. Campbell MP, Royle L, Radcliffe CM et al. GlycoBase and AutoGU: tools for HPLC-based glycan analysis. Bioinformatics 200824:1214-6.
31. Keusch J, Lydyard PM, Delves PJ. The effect on IgG glycosylation of altering beta1, 4-galactosyltransferase-1 activity in B cells. Glycobiology 19988:1215-20.
32. Keusch J, Lydyard PM, Berger EG et al. B lymphocyte galactosyltransferase protein levels in normal individuals and in patients with rheumatoid arthritis. Glycoconj J 199815:1093-7.
33. Axford JS, Lydyard PM, Isenberg DA et al. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 19872:1486-8.
34. Furukawa K, Matsuta K, Takeuchi F et al. Kinetic study of a galactosyltransferase in the B cells of patients with rheumatoid arthritis. Int Immunol 19902:105-12.
35. Wilson IBH, Platt FM, Isenberg DA et al. Aberrant control of galactosyltransferase in peripheral B lymphocytes and Epstein-Barr virus transformed B-lymphoblasts from patients with rheumatoid arthritis. J Rheumatol 199320: 1282-7.
36. Axford JS, Sumar N, Alavi A et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 199289:1021-31.
37. Jelinek DF, Lipsky PE. Enhancement of human B-cell proliferation and differentiation by tumor-necrosisfactor-alpha and interleukin-1. J Immunol 1987139: 2970-6.
38. Yang X, Lehotay M, Anastassiades T et al. The effect of TNF-alpha on glycosylation pathways in bovine synoviocytes. Biochem Cell Biol 200482:559-68.
39. Elliott MA, Jorgensen HG, Smith KD. Hypersialylation of a1-acid glycoprotein expressed by sufferers of rheumatoid arthritis. Pharm Pharmacol Commun 19984: 545-7.
40. Feelders RA, Vreugdenhil G, de Jong G et al. Transferrin microheterogeneity in rheumatoid arthritis. Relation with disease activity and anemia of chronic disease. Rheumatol Int 199212:195-9.
41. Thompson S, Kelly CA, Griffiths ID et al. Abnormallyfucosylated serum haptoglobins in patients with inflammatory joint disease. Clin Chim Acta 1989184:251-8.
42. Sarrats A, Saldova R, Pla E et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl 20104:432-48.
43. Arnold JN, Saldova R, Hamid UM et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 20088:3284-93.
44. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 200810:212.
45. Harvey DJ, Merry AH, Royle L et al. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 20099:3796-801.